For nearly four decades, from our first API sale in the mid-1980s to emerging as a trusted partner for the development and commercialisation of new molecules, we have constantly reinvented ourselves, focussing on building the right capabilities to win in changing market conditions.
|
Period
|
Focus
|
Achievements and Activities
|
| 1984-2013 |
Building our reputation
as a quality-focussed
organization |
- Large volume generic APIs and intermediates manufacturing
- Two US FDA-approved manufacturing facilities and a
dedicated R&D centre
- 3 cGMP manufacturing facilities
- Developed reputation as a reliable supplier with top global
generics formulators
- Strategic alignment of business towards niche APIs and
custom manufacturing solutions
|
| 2013-2022 |
Building a portfolio
of differentiated
products and business |
- Specialty APIs manufacturing
- Organic growth of Custom Manufacturing Solutions
business – the emergence of strategy with a focus on
biotech companies
- R&D facility approved by US FDA
- Emphasis on uninterrupted supply and quality
- Acquisition of advanced intermediates and API facility
|
| 2022 onwards |
Accelerating growth
and fortifying for a
stronger future |
- Strong performance in the CMS business
- Over 75 live commercial and development projects
- Strengthening capabilities and capacities
- Growing our reputation as a partner for biotech companies
- Project and customer management
- Building our GDS pipeline with a focus on technology
differentiation including peptides
- Maintaining leadership position in key molecules
- Lifecycle management of commercial products
- Crossed ₹1,000 crores revenue
|
Evolving our revenue mix
Evolution of GDS Vertical
| 1984-2013 |
- Focus on large volume products with portfolio dictated by customers
|
| 2013-2022 |
- Shift in focus to differentiated/specialty products with a selective portfolio approach
- Explored modification of product and customer mix
- Established a portfolio of diverse drug classes with market leadership in inhalation products a
new oral anticoagulant (NOACs), among others
|
| 2022 onwards |
- Building a strategic portfolio with products differentiated on technology including
generic peptides
|
Evolution of CMS Vertical
| 2008-2012 |
- Laying the business foundation
|
| 2012-2016 |
- Leveraging our GDS portfolio for relationships
- Offering custom synthesis services
- Laying the building blocks for peptide business
|
| 2016-2020 |
- Partnering with small biotech companies having late-stage candidates
|
| 2020 onwards |
- Continuing to target lucrative early and late-stage clinical candidates
- Building new capabilities and strategic partnerships
|
Our Business Segments
